Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma

Cancer Letters

Volumn 314, Issue 1, 2012, Pages 24-33

  Dunn, Jeffrey H ^a   Ellis, Lixia Z ^a   Fujita, Mayumi ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ASC; Cancer; IL 1 ; Inflammasome; Inflammation; Melanoma

Indexed keywords

CANAKINUMAB; CASPASE 1 INHIBITOR; CASPASE INHIBITOR; CRYOPYRIN; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RANTES; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT ONSET STILL DISEASE; BEHCET DISEASE; CANCER RESEARCH; CARCINOGENESIS; CINCA SYNDROME; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVATION; GOUT; HUMAN; IMMUNE RESPONSE; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 82355175161     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.001     Document Type: Review

References (163)

1. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
2. Coca S., Perez-Piqueras J., Martinez D., Colmenarejo A., Saez M.A., Vallejo C., Martos J.A., Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997, 79:2320-2328.
3. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56:4625-4629.
4. Ribatti D., Ennas M.G., Vacca A., Ferreli F., Nico B., Orru S., Sirigu P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest. 2003, 33:420-425.
5. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
6. Balkwill F., Coussens L.M. Cancer: an inflammatory link. Nature 2004, 431:405-406.
7. Lu C., Kerbel R.S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol. 1993, 120:1281-1288.
8. Apte R.N., Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?. Immunol. Rev. 2008, 222:222-241.
9. Dinarello C.A. Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev. 2010, 29:317-329.
10. Bar D., Apte R.N., Voronov E., Dinarello C.A., Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 2004, 18:161-163.
11. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C.A., Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 2003, 100:2645-2650.
12. Song X., Voronov E., Dvorkin T., Fima E., Cagnano E., Benharroch D., Shendler Y., Bjorkdahl O., Segal S., Dinarello C.A., Apte R.N. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J. Immunol. 2003, 171:6448-6456.
13. Apte R.N., Krelin Y., Song X., Dotan S., Recih E., Elkabets M., Carmi Y., Dvorkin T., White R.M., Gayvoronsky L., Segal S., Voronov E. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur. J. Cancer 2006, 42:751-759.
14. Apte R.N., Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 2002, 12:277-290.
15. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
16. Ogura Y., Sutterwala F.S., Flavell R.A. The inflammasome: first line of the immune response to cell stress. Cell 2006, 126:659-662.
17. Mariathasan S., Monack D.M. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat. Rev. Immunol. 2007, 7:31-40.
18. Franchi L., Eigenbrod T., Munoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 2009, 10:241-247.
19. Lachmann H.J., Lowe P., Felix S.D., Rordorf C., Leslie K., Madhoo S., Wittkowski H., Bek S., Hartmann N., Bosset S., Hawkins P.N., Jung T. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 2009, 206:1029-1036.
20. Okamoto M., Liu W., Luo Y., Tanaka A., Cai X., Norris D.A., Dinarello C.A., Fujita M. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 2010, 285:6477-6488.
21. Siegel R., Ward E., Brawley O., Jemal A., Cancer statistics The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
22. Hall H.I., Miller D.R., Rogers J.D., Bewerse B. Update on the incidence and mortality from melanoma in the United States. J. Am. Acad. Dermatol. 1999, 40:35-42.
23. Nikolova P.N., Pawelec G.P., Mihailova S.M., Ivanova M.I., Myhailova A.P., Baltadjieva D.N., Marinova D.I., Ivanova S.S., Naumova E.J. Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol. Immunother. 2007, 56:371-379.
24. Howell W.M., Turner S.J., Theaker J.M., Bateman A.C. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur. J. Immunogenet. 2003, 30:409-414.
25. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
26. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
27. Tyler D.S., Francis G.M., Frederick M., Tran A.H., Ordonez N.G., Smith J.L., Eton O., Ross M., Grimm E.A. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J. Interferon Cytokine Res. 1995, 15:331-340.
28. Elaraj D.M., Weinreich D.M., Varghese S., Puhlmann M., Hewitt S.M., Carroll N.M., Feldman E.D., Turner E.M., Alexander H.R. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin. Cancer Res. 2006, 12:1088-1096.
29. Weinreich D.M., Elaraj D.M., Puhlmann M., Hewitt S.M., Carroll N.M., Feldman E.D., Turner E.M., Spiess P.J., Alexander H.R. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res. 2003, 63:5957-5961.
30. Burrows F.J., Haskard D.O., Hart I.R., Marshall J.F., Selkirk S., Poole S., Thorpe P.E. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res. 1991, 51:4768-4775.
31. McKenzie R.C., Park E.S., Brown W.R., Shivji G.S., Sauder D.N. Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and -6. Photodermatol. Photoimmunol. Photomed. 1994, 10:74-79.
32. Vidal-Vanaclocha F., Amezaga C., Asumendi A., Kaplanski G., Dinarello C.A. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res. 1994, 54:2667-2672.
33. Vidal-Vanaclocha F., Alvarez A., Asumendi A., Urcelay B., Tonino P., Dinarello C.A. Interleukin 1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J. Natl. Cancer Inst. 1996, 88:198-205.
34. Song X., Krelin Y., Dvorkin T., Bjorkdahl O., Segal S., Dinarello C.A., Voronov E., Apte R.N. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 2005, 175:8200-8208.
35. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Folsch U.R., Schafer H. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002, 62:910-916.
36. Muerkoster S., Wegehenkel K., Arlt A., Witt M., Sipos B., Kruse M.L., Sebens T., Kloppel G., Kalthoff H., Folsch U.R., Schafer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004, 64:1331-1337.
37. Gyorffy B., Surowiak P., Kiesslich O., Denkert C., Schafer R., Dietel M., Lage H. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer 2006, 118:1699-1712.
38. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
39. Branicki W., Brudnik U., Kupiec T., Wolanska-Nowak P., Wojas-Pelc A. Determination of phenotype associated SNPs in the MC1R gene. J. Forensic Sci. 2007, 52:349-354.
40. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66:1-9.
41. Netea M.G., Nold-Petry C.A., Nold M.F., Joosten L.A., Opitz B., van der Meer J.H., van de Veerdonk F.L., Ferwerda G., Heinhuis B., Devesa I., Funk C.J., Mason R.J., Kullberg B.J., Rubartelli A., van der Meer J.W., Dinarello C.A. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113:2324-2335.
42. Dinarello C.A., Ikejima T., Warner S.J., Orencole S.F., Lonnemann G., Cannon J.G., Libby P. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 1987, 139:1902-1910.
43. Ghezzi P., Dinarello C.A. IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. J. Immunol. 1988, 140:4238-4244.
44. Schindler R., Ghezzi P., Dinarello C.A. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J. Immunol. 1990, 144:2216-2222.
45. Warner S.J., Auger K.R., Libby P. Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J. Immunol. 1987, 139:1911-1917.
46. Warner S.J., Auger K.R., Libby P. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J. Exp. Med. 1987, 165:1316-1331.
47. Sun W.H., Kreisle R.A., Phillips A.W., Ershler W.B. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res. 1992, 52:5412-5415.
48. Oppenheim J.J., Zachariae C.O., Mukaida N., Matsushima K. Properties of the novel proinflammatory supergene " intercrine" cytokine family. Annu. Rev. Immunol. 1991, 9:617-648.
49. Schadendorf D., Moller A., Algermissen B., Worm M., Sticherling M., Czarnetzki B.M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol. 1993, 151:2667-2675.
50. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 2003, 170:3369-3376.
51. Rollins B.J., Walz A., Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991, 78:1112-1116.
52. Jiang Y., Beller D.I., Frendl G., Graves D.T. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J. Immunol. 1992, 148:2423-2428.
53. Colotta F., Dower S.K., Sims J.E., Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol. Today 1994, 15:562-566.
54. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
55. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
56. Janeway C.A., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002, 20:197-216.
57. Dinarello C.A. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 2002, 20:S1-13.
58. Rubartelli A., Cozzolino F., Talio M., Sitia R. A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. EMBO J. 1990, 9:1503-1510.
59. Wewers M.D. IL-1beta: an endosomal exit. Proc. Natl. Acad. Sci. USA 2004, 101:10241-10242.
60. Qu Y., Franchi L., Nunez G., Dubyak G.R. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 2007, 179:1913-1925.
61. Andrei C., Margiocco P., Poggi A., Lotti L.V., Torrisi M.R., Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc. Natl. Acad. Sci. USA 2004, 101:9745-9750.
62. Dinarello C.A. Blocking IL-1 in systemic inflammation. J. Exp. Med. 2005, 201:1355-1359.
63. Dinarello C.A. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005, 52:1960-1967.
64. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 2002, 10:417-426.
65. Tschopp J., Martinon F., Burns K. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell. Biol. 2003, 4:95-104.
66. Stehlik C., Fiorentino L., Dorfleutner A., Bruey J.M., Ariza E.M., Sagara J., Reed J.C. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J. Exp. Med. 2002, 196:1605-1615.
67. Mariathasan S. ASC, Ipaf and Cryopyrin/Nalp3: bona fide intracellular adapters of the caspase-1 inflammasome. Microbes Infect. 2007, 9:664-671.
68. Davis B.K., Roberts R.A., Huang M.T., Willingham S.B., Conti B.J., Brickey W.J., Barker B.R., Kwan M., Taxman D.J., Accavitti-Loper M.A., Duncan J.A., Ting J.P. Cutting edge: NLRC5-dependent activation of the inflammasome. J. Immunol. 2011, 186:1333-1337.
69. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
70. Bauernfeind F., Ablasser A., Bartok E., Kim S., Schmid-Burgk J., Cavlar T., Hornung V. Inflammasomes: current understanding and open questions. Cell. Mol. Life Sci. 2011, 68:765-783.
71. Davis B.K., Wen H., Ting J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu. Rev. Immunol. 2011, 29:707-735.
72. Franchi L., Muñoz-Planillo R., Reimer T., Eigenbrod T., Núñez G. Inflammasomes as microbial sensors. Eur. J. Immunol. 2010, 40:611-615.
73. Faustin B., Lartigue L., Bruey J.M., Luciano F., Sergienko E., Bailly-Maitre B., Volkmann N., Hanein D., Rouiller I., Reed J.C. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol. Cell 2007, 25:713-724.
74. Poyet J.L., Srinivasula S.M., Tnani M., Razmara M., Fernandes-Alnemri T., Alnemri E.S. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J. Biol. Chem. 2001, 276:28309-28313.
75. Franchi L., Stoolman J., Kanneganti T.D., Verma A., Ramphal R., Núñez G. Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur. J. Immunol. 2007, 37:3030-3039.
76. Suzuki T., Franchi L., Toma C., Ashida H., Ogawa M., Yoshikawa Y., Mimuro H., Inohara N., Sasakawa C., Nuñez G. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog. 2007, 3:e111.
77. Mariathasan S., Newton K., Monack D.M., Vucic D., French D.M., Lee W.P., Roose-Girma M., Erickson S., Dixit V.M. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004, 430:213-218.
78. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
79. Martinon F., Agostini L., Meylan E., Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 2004, 14:1929-1934.
80. McCall S.H., Sahraei M., Young A.B., Worley C.S., Duncan J.A., Ting J.P., Marriott I. Osteoblasts express NLRP3, a nucleotide-binding domain and leucine-rich repeat region containing receptor implicated in bacterially induced cell death. J. Bone Miner. Res. 2008, 23:30-40.
81. Hornung V., Ablasser A., Charrel-Dennis M., Bauernfeind F., Horvath G., Caffrey D.R., Latz E., Fitzgerald K.A. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
82. Fernandes-Alnemri T., Yu J.W., Datta P., Wu J., Alnemri E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458:509-513.
83. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007, 14:10-22.
84. Boyden E.D., Dietrich W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 2006, 38:240-244.
85. Hsu L.C., Ali S.R., McGillivray S., Tseng P.H., Mariathasan S., Humke E.W., Eckmann L., Powell J.J., Nizet V., Dixit V.M., Karin M. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc. Natl. Acad. Sci. USA 2008, 105:7803-7808.
86. Sutterwala F.S., Mijares L.A., Li L., Ogura Y., Kazmierczak B.I., Flavell R.A. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J. Exp. Med. 2007, 204:3235-3245.
87. Miao E.A., Ernst R.K., Dors M., Mao D.P., Aderem A. Pseudomonas aeruginosa activates caspase 1 through Ipaf. Proc. Natl. Acad. Sci. USA 2008, 105:2562-2567.
88. Amer A., Franchi L., Kanneganti T.D., Body-Malapel M., Ozoren N., Brady G., Meshinchi S., Jagirdar R., Gewirtz A., Akira S., Nunez G. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J. Biol. Chem. 2006, 281:35217-35223.
89. Muruve D.A., Pétrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., Parks R.J., Tschopp J. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452:103-107.
90. Choubey D., Panchanathan R. Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol. Lett. 2008, 119:32-41.
91. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 2009, 183:787-791.
92. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., Lee W.P., Weinrauch Y., Monack D.M., Dixit V.M. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
93. Harder J., Franchi L., Muñoz-Planillo R., Park J.H., Reimer T., Núñez G. Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. J. Immunol. 2009, 183:5823-5829.
94. Gurcel L., Abrami L., Girardin S., Tschopp J., van der Goot F.G. Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006, 126:1135-1145.
95. Kim S., Bauernfeind F., Ablasser A., Hartmann G., Fitzgerald K.A., Latz E., Hornung V. Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur. J. Immunol. 2010, 40:1545-1551.
96. Munoz-Planillo R., Franchi L., Miller L.S., Nunez G. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J. Immunol. 2009, 183:3942-3948.
97. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9:857-865.
98. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
99. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11:136-140.
100. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nunez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
101. Cassel S.L., Eisenbarth S.C., Iyer S.S., Sadler J.J., Colegio O.R., Tephly L.A., Carter A.B., Rothman P.B., Flavell R.A., Sutterwala F.S. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. USA 2008, 105:9035-9040.
102. Dostert C., Pétrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
103. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9:847-856.
104. Feldmeyer L., Keller M., Niklaus G., Hohl D., Werner S., Beer H.D. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr. Biol. 2007, 17:1140-1145.
105. Cruz C.M., Rinna A., Forman H.J., Ventura A.L., Persechini P.M., Ojcius D.M. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem. 2007, 282:2871-2879.
106. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
107. Dorfleutner A., Talbott S.J., Bryan N.B., Funya K.N., Rellick S.L., Reed J.C., Shi X., Rojanasakul Y., Flynn D.C., Stehlik C. A shope fibroma virus PYRIN-only protein modulates the host immune response. Virus Genes 2007, 35:685-694.
108. Benedict C.A., Ware C.F. Poxviruses aren't stuPYD. Immunity 2005, 23:553-555.
109. Mayor A., Martinon F., De Smedt T., Petrilli V., Tschopp J. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat. Immunol. 2007, 8:497-503.
110. Bruey J.M., Bruey-Sedano N., Luciano F., Zhai D., Balpai R., Xu C., Kress C.L., Bailly-Maitre B., Li X., Osterman A., Matsuzawa S., Terskikh A.V., Faustin B., Reed J.C. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell 2007, 129:45-56.
111. Faustin B., Chen Y., Zhai D., Le Negrate G., Lartigue L., Satterthwait A., Reed J.C. Mechanism of Bcl-2 and Bcl-X(L) inhibition of NLRP1 inflammasome: loop domain-dependent suppression of ATP binding and oligomerization. Proc. Natl. Acad. Sci. USA 2009, 106:3935-3940.
112. Guarda G., Dostert C., Staehli F., Cabalzar K., Castillo R., Tardivel A., Schneider P., Tschopp J. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009, 460:269-273.
113. Masumoto J., Taniguchi S., Ayukawa K., Sarvotham H., Kishino T., Niikawa N., Hidaka E., Katsuyama T., Higuchi T., Sagara J. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 1999, 274:33835-33838.
114. McConnell B.B., Vertino P.M. TMS1/ASC: the cancer connection. Apoptosis 2004, 9:5-18.
115. Bryan N.B., Dorfleutner A., Kramer S.J., Yun C., Rojanasakul Y., Stehlik C. Differential splicing of the apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) regulates inflammasomes. J. Inflamm. (Lond.) 2010, 7:23.
116. Bryan N.B., Dorfleutner A., Rojanasakul Y., Stehlik C. Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain. J. Immunol. 2009, 182:3173-3182.
117. Dorfleutner A., Bryan N.B., Talbott S.J., Funya K.N., Rellick S.L., Reed J.C., Shi X., Rojanasakul Y., Flynn D.C., Stehlik C. Cellular pyrin domain-only protein 2 is a candidate regulator of inflammasome activation. Infect. Immun. 2007, 75:1484-1492.
118. Stehlik C., Dorfleutner A. COPs and POPs: modulators of inflammasome activity. J. Immunol. 2007, 179:7993-7998.
119. Shoham N.G., Centola M., Mansfield E., Hull K.M., Wood G., Wise C.A., Kastner D.L. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA 2003, 100:13501-13506.
120. Wise C.A., Gillum J.D., Seidman C.E., Lindor N.M., Veile R., Bashiardes S., Lovett M. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 2002, 11:961-969.
121. Chae J.J., Cho Y.H., Lee G.S., Cheng J., Liu P.P., Feigenbaum L., Katz S.I., Kastner D.L. Gain-of-function pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011, 34:755-768.
122. Franchi L., Núñez G. A new twist on the PYRIN mediterranean coast. Immunity 2011, 34:695-697.
123. Jin Y., Mailloux C.M., Gowan K., Riccardi S.L., LaBerge G., Bennett D.C., Fain P.R., Spritz R.A. NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 2007, 356:1216-1225.
124. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P.N. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 2009, 360:2416-2425.
125. Feldmann J., Prieur A.M., Quartier P., Berquin P., Certain S., Cortis E., Teillac-Hamel D., Fischer A., de Saint Basile G. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 2002, 71:198-203.
126. Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., Stein L., Russo R., Goldsmith D., Dent P., Rosenberg H.F., Austin F., Remmers E.F., Balow J.E., Rosenzweig S., Komarow H., Shoham N.G., Wood G., Jones J., Mangra N., Carrero H., Adams B.S., Moore T.L., Schikler K., Hoffman H., Lovell D.J., Lipnick R., Barron K., O'Shea J.J., Kastner D.L., Goldbach-Mansky R. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002, 46:3340-3348.
127. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., Kim H.J., Brewer C., Zalewski C., Wiggs E., Hill S., Turner M.L., Karp B.I., Aksentijevich I., Pucino F., Penzak S.R., Haverkamp M.H., Stein L., Adams B.S., Moore T.L., Fuhlbrigge R.C., Shaham B., Jarvis J.N., O'Neil K., Vehe R.K., Beitz L.O., Gardner G., Hannan W.P., Warren R.W., Horn W., Cole J.L., Paul S.M., Hawkins P.N., Pham T.H., Snyder C., Wesley R.A., Hoffmann S.C., Holland S.M., Butman J.A., Kastner D.L. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 2006, 355:581-592.
128. Chae J.J., Wood G., Masters S.L., Richard K., Park G., Smith B.J., Kastner D.L. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. USA 2006, 103:9982-9987.
129. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005, 52:1794-1803.
130. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005, 201:1479-1486.
131. Simon A., van der Meer J.W. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R86-98.
132. Botsios C., Sfriso P., Furlan A., Punzi L., Dinarello C.A. Resistant Behcet disease responsive to anakinra. Ann. Intern. Med. 2008, 149:284-286.
133. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 2007, 9:R28.
134. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., Kaiser N., Halban P.A., Donath M.Y. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110:851-860.
135. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
136. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E.W., Pham T.H., Booty M., Estes J.D., Sandler N.G., Plass N., Stone D.L., Turner M.L., Hill S., Butman J.A., Schneider R., Babyn P., El-Shanti H.I., Pope E., Barron K., Bing X., Laurence A., Lee C.C., Chapelle D., Clarke G.I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B.D., Gregersen P.K., van Hagen P.M., Hak A.E., Huizing M., Rahman P., Douek D.C., Remmers E.F., Kastner D.L., Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 2009, 360:2426-2437.
137. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., Hessner M.J., Verbsky J. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 2009, 360:2438-2444.
138. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
139. P. Sun, Q. Ben, S. Tu, W. Dong, X. Qi, Y. Wu, Serum interleukin-33 levels in patients with gastric cancer, Dig. Dis. Sci. (2011).
140. Allen I.C., TeKippe E.M., Woodford R.M., Uronis J.M., Holl E.K., Rogers A.B., Herfarth H.H., Jobin C., Ting J.P. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 2010, 207:1045-1056.
141. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
142. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J.L., Schlemmer F., Tasdemir E., Uhl M., Génin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., André F., Lidereau R., McLaughlin N.M., Haynes N.M., Smyth M.J., Kroemer G., Zitvogel L. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
143. Zheng J.N., Pei D.S., Mao L.J., Liu X.Y., Sun F.H., Zhang B.F., Liu Y.Q., Liu J.J., Li W., Han D. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther. 2010, 17:28-36.
144. Nishio S., Yamada N., Ohyama H., Yamanegi K., Nakasho K., Hata M., Nakamura Y., Fukunaga S., Futani H., Yoshiya S., Ueda H., Taniguchi M., Okamura H., Terada N. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci. 2008, 99:113-120.
145. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., Fuentes A.M., Anasagasti M.J., Martin J., Carrascal T., Walsh P., Reznikov L.L., Kim S.H., Novick D., Rubinstein M., Dinarello C.A. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. USA 2000, 97:734-739.
146. Cho D., Song H., Kim Y.M., Houh D., Hur D.Y., Park H., Yoon D., Pyun K.H., Lee W.J., Kurimoto M., Kim Y.B., Kim Y.S., Choi I. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res. 2000, 60:2703-2709.
147. L.Z. Ellis, W. Liu, Y. Luo, M. Okamoto, D. Qu, J.H. Dunn, M. Fujita, Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem. Biophys. Res. Commun., (2011), in press, [Epub ahead of print]. doi:10.1016/j./bbrc.2011.09.115.
148. van Deventer H.W., Burgents J.E., Wu Q.P., Woodford R.M., Brickey W.J., Allen I.C., McElvania-Tekippe E., Serody J.S., Ting J.P. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 2010, 70:10161-10169.
149. Normand S., Delanoye-Crespin A., Bressenot A., Huot L., Grandjean T., Peyrin-Biroulet L., Lemoine Y., Hot D., Chamaillard M. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl. Acad. Sci. USA 2011, 108:9601-9606.
150. Hu B., Elinav E., Flavell R.A. Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 2011, 10:1936-1939.
151. Chen G.Y., Shaw M.H., Redondo G., Nunez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 2008, 68:10060-10067.
152. Chen I.F., Ou-Yang F., Hung J.Y., Liu J.C., Wang H., Wang S.C., Hou M.F., Hortobagyi G.N., Hung M.C. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Mol. Cancer Ther. 2006, 5:1-7.
153. Ohtsuka T., Ryu H., Minamishima Y.A., Macip S., Sagara J., Nakayama K.I., Aaronson S.A., Lee S.W. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat. Cell Biol. 2004, 6:121-128.
154. Moriai R., Tsuji N., Kobayashi D., Yagihashi A., Namiki Y., Takahashi H., Watanabe N. A proapoptotic caspase recruitment domain protein gene, TMS1, is hypermethylated in human breast and gastric cancers. Anticancer Res. 2002, 22:4163-4168.
155. Stone A.R., Bobo W., Brat D.J., Devi N.S., Van Meir E.G., Vertino P.M. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am. J. Pathol. 2004, 165:1151-1161.
156. Guan X., Sagara J., Yokoyama T., Koganehira Y., Oguchi M., Saida T., Taniguchi S. ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int. J. Cancer 2003, 107:202-208.
157. Das P.M., Ramachandran K., Vanwert J., Ferdinand L., Gopisetty G., Reis I.M., Singal R. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol. Cancer 2006, 5:28.
158. Taxman D.J., Holley-Guthrie E.A., Huang M.T., Moore C.B., Bergstralh D.T., Allen I.C., Lei Y., Gris D., Ting J.P. The NLR adaptor ASC/PYCARD regulates DUSP10, mitogen-activated protein kinase (MAPK), and chemokine induction independent of the inflammasome. J. Biol. Chem. 2011, 286:19605-19616.
159. den Broeder A.A., de Jong E., Franssen M.J., Jeurissen M.E., Flendrie M. F.H. van den Hoogen, Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann. Rheum. Dis. 2006, 65:760-762.
160. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., Weinstein S.P., Belomestnov P., Yancopoulos G.D., Stahl N., Mellis S.J. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008, 58:2443-2452.
161. Stack J.H., Beaumont K., Larsen P.D., Straley K.S., Henkel G.W., Randle J.C., Hoffman H.M. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J. Immunol. 2005, 175:2630-2634.
162. Nigrovic P.A., Mannion M., Prince F.H., Zeft A., Rabinovich C.E., van Rossum M.A., Cortis E., Pardeo M., Miettunen P.M., Janow G., Birmingham J., Eggebeen A., Janssen E., Shulman A.I., Son M.B., Hong S., Jones K., Ilowite N.T., Cron R.Q., Higgins G.C. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011, 63:545-555.
163. Cohen S.B., Woolley J.M., Chan W. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. 2003, 30:225-231.